semaglutide and cardiac risk cardiovascular outcomes align more closely with attained dose than achieved weight loss VisualAbstract: Semaglutide and Cardiovascular Outcomes

You can take Wegovy with rheumatoid arthritis

Doctors uncover surprising causes, like artificial sweeteners and dehydration, and share easy fixes to calm the spasms.

Water volumes, unit conversions, titration schedules, and storage guidelines for accurate dosing.

Liver transcriptomics revealed that semaglutide may interfere with the growth of malnourished juvenile mice by altering circadian rhythm and thermogenesis

Industry experts congratulated Eli Lilly and Novo Nordisk for persisting in the GLP-1 space and discussed how the next wave of innovation is not always clear.

Zepbound patients maintained ~80% Better absorption: Non-peptide formulation means easier absorption without dietary limitations Market Impact: While Novo Nordisk recently launched oral Wegovy as the first oral GLP-1 approved for weight loss, Lilly's orforglipron could offer competitive advantages with its flexible dosing and absorption profile